• Explore /
  • Poster
  • / Prediction of response to neoadjuvant therapy (NAT) in early breast cancer (EBC) at community hospitals: SimBioSys TumorScope Validation Study.

Prediction of response to neoadjuvant therapy (NAT) in early breast cancer (EBC) at community hospitals: SimBioSys TumorScope Validation Study.

Abstract Poster

Authors

null

John R. Pfeiffer

SimBioSys, Inc., Chicago, IL

John R. Pfeiffer , Karen Zwicky , Tushar Pandey , Anu K. Antony , The SimBioSys Team , John A. Cole Jr., Clifford Wolf

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 598)

DOI

10.1200/JCO.2022.40.16_suppl.598

Abstract #

598

Poster Bd #

369

Abstract Disclosures

Similar Posters

First Author: Jiani Wang

First Author: S. B. Edge

First Author: Kay T Yeung

First Author: Rebecca Arielle Shatsky